NCT06661876Recruiting
Cardiac RadiothErapy For hEart faiLure
Source: ClinicalTrials.gov · Last updated 1 Dec 2025
Brief summary (registry, in English)
Preliminary data suggests that patients suffering from advanced refractory heart failure (HF) could benefit from single low dose whole heart external beam radiotherapy (EBRT). Objective: To explore in our center the efficacy of administering a EBRT treatment of 5Gy to the whole heart in patients with advanced and refractory HF. The hypothesis is that 5Gy EBRT to the whole heart can improve the left ventricular ejection fraction (LVEF) of these patients by a clinically relevant 5%. Main study endpoints: The primary aim is to explore the efficacy of EBRT treatment for advanced refractory HF. Secondary endpoints include an assessment of safety, overall survival, hospital admissions, late toxicity, quality of life and the effect of the treatment on other heart function indicators (left ventricular volumes, NT-proBNP, Troponine, High sensitive CRP).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 21 Oct 2024
- Start date
- 1 Jan 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Diseases
- Heart failure
- NCT number
- NCT06661876
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 1 Jan 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous radiotherapy with cardiac involvement
Other illness
- Eligible or in consideration for heart transplantation
- Any condition that is deemed a contraindication in the judgment of the investigators
Other
- Pregnancy or breastfeeding
Who the study is looking for
- Patient ≥ 18 years
- Advanced refractory HF NYHA class II, III or IV
- Stable HF for the last 6 months with maximal guideline-directed HF therapy
- Ischemic or dilated cardiomyopathy
- LVEF at baseline ≤ 35%
- Ability to give a written informed consent and willingness to return for follow-up
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UZ Leuven Coordinator of this site? Confirm its status | Leuven | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.